The biopharmaceutical industry contemplates product innovation within the changing landscape of healthcare.
Rita E. Numerof, PhD
Advertisement
Rita E. Numerof, PhD, is the president at Numerof & Associates, Inc.
Articles by Rita E. Numerof, PhD
Rather than seeking a single indication for one large group, the orphan-drug approach segments the market for a drug more minutely.
The industry must be prepared for the impact of the sweeping changes expected from the new legislation.
Advertisement
Latest Updated Articles
The Affordable Care Act's Impact on Innovation in BiopharmaPublished: February 1st 2014 | Updated:
- The Growing Orphan-Drug Paradigm
Published: April 1st 2012 | Updated:
Are You Ready for a Post-Reform World?Published: May 1st 2010 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
3
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
4
Industry Leaders Detail Transformational Strategies to Mainstream CAR-T Care
5
